 Kindred Biosciences NASDAQ:KIN was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to ... 